

# KDIGO 2020 GUIDELINE NOW RECOMMENDS K<sup>+</sup> BINDERS

for the management of diabetic CKD patients with hyperkalemia on ACEi and ARB therapy\*




## KEY HIGHLIGHTS

- ▶ ACEi and ARB modification **should be a last resort** to manage hyperkalemia<sup>1</sup>
- ▶ Hyperkalemia should be **managed with other measures** before considering ACEi or ARB down-titration or discontinuation<sup>1</sup>
- ▶ **Consider a K<sup>+</sup> binder** for the management of hyperkalemia in patients on ACEi and ARB therapy<sup>1</sup>

## THE UPDATED KDIGO 2020 GUIDELINE FOR DIABETES MANAGEMENT IN CHRONIC KIDNEY DISEASE STATES<sup>1</sup>:

- ▶ In patients with diabetes, hypertension, and albuminuria, ACEi and ARB treatment should be initiated and titrated to the maximum approved dose that is tolerated<sup>1</sup>
- ▶ ACEi and ARB treatment should only be reduced or discontinued if serum K<sup>+</sup> levels cannot be otherwise managed<sup>1</sup>
- ▶ Recommendations to manage hyperkalemia include reviewing concurrent drugs, moderate K<sup>+</sup> intake, initiating diuretics or oral sodium bicarbonate in appropriate patients, and use of a gastrointestinal cation exchanger such as a K<sup>+</sup> binder<sup>1</sup>
- ▶ K<sup>+</sup> binders should be considered to decrease serum K<sup>+</sup> levels after other measures have failed, rather than decreasing or discontinuing ACEi and ARB treatment<sup>1</sup>

## KDIGO 2020 recommendations for monitoring and dose adjustment during ACEi and ARB therapy<sup>1</sup>



ACEi=angiotensin-converting enzyme inhibitors; AKI=acute kidney injury; ARB=angiotensin II receptor blocker; CKD=chronic kidney disease; GI=gastrointestinal; K<sup>+</sup>=potassium; NSAIDs=nonsteroidal anti-inflammatory drugs; RAAS=renin-angiotensin-aldosterone system.

\*This guideline is specifically for the management of diabetes in chronic kidney disease, which only represents a subset of patients with hyperkalemia.

Reference: 1. KDIGO 2020 Guideline for Diabetes Management in Chronic Kidney Disease. *Kidney Int.* 2020;98(suppl 4):S1-S115.



©2020 AstraZeneca. All rights reserved. US-47510 Last Updated 12/20.

**CONSIDER K<sup>+</sup> BINDERS FOR THE TREATMENT OF HYPERKALEMIA IN YOUR PATIENTS ON ACEi OR ARB THERAPY.**

**REVIEW KDIGO 2020 GUIDELINE**



Recommendation 1.2.1, Practice Point 1.2.5, and Practice Point 1.2.6.